Foresee Pharmaceuticals announces the Casppian Phase 3 Study Meets Primary Efficacy Endpoint, Demonstrating Robust LH Suppression with 6-Month Dosing Interval of leuprolide ...

FP-001 42 mg is an investigational, sustained-release formulation of a GnRH agonist being developed for the treatment of CPP. It is designed to provide continuous suppression of gonadotropin secretion ...
Le Lézard

CPP Investments to Acquire Indirect Minority Stake in Castrol

Canada Pension Plan Investment Board ("CPP Investments"), today announced an agreement to acquire an indirect non-controlling interest in Castrol, a global leader in lubricants, alongside Stonepeak, a ...